Results 1 to 10 of about 1,521,190 (96)

HER-2 therapeutic vaccine is not hampered by concurrent HER-2 monoclonal antibody [PDF]

npj Vaccines
ES2B-C001 represents a new generation of vaccines based on virus-like particles (VLP) that display the full extracellular domain of HER-2 and has now entered clinical development.
Maria Sofia Semprini, Chiara Cappello, Laura Scalambra, Olga Maria Pittino, Stefania Angelicola, Patrizia Nanni, Pier-Luigi Lollini, Francesca Ruzzi   +7 more
doaj   +2 more sources

Screening and docking molecular studies of natural products targeting overexpressed receptors HER-2 in breast cancer [PDF]

Archives of Razi Institute
The first cancer to strike a community is breast cancer. Because of its extremely high mitotic activity, breast cancer that tests positive for HER 2 is thought to have a bad prognosis.
Nesrine Lenchi, Naima Maouche, Souad Khemili-Talbi   +2 more
doaj   +2 more sources

Human epidermal growth factor receptor 2 expression in gastric cancer patients treated with curative intent gastrectomy [PDF]

Korean Journal of Clinical Oncology, 2017
Purpose This study aimed to clarify the association between human epidermal growth factor receptor 2 (HER-2) status and the clinicopathologic factors of patients who underwent curative intent gastrectomy.
Min Kyu Kim, Sang Eok Lee, Jang Sihn Sohn, In Seok Choi, Ju Ik Moon, Dae Sung Yoon, Ki Won Chun, Hye Yoon Lee, Nak Song Sung, Si Min Park, Won Jun Choi   +10 more
doaj   +1 more source

Controversies of radiotherapy in human epidermal growth factor receptor (HER)-2 positive breast cancer patients

Biomedical Papers, 2021
Tumor biology plays a crucial role in the systemic treatment, specifically in HER2-positive tumors. Distinct biological behavior of breast cancer subtypes is associated with different rates of locoregional recurrence (LRR).
Iveta Kolarova, Bohuslav Melichar, Jaroslav Vanasek, Ales Ryska, Katerina Horackova, Jiri Petera, Milan Vosmik, Igor Sirak, Martin Dolezel   +8 more
doaj   +1 more source

Interleukine-2 serum level in breast cancer patients [PDF]

Caspian Journal of Internal Medicine, 2023
Background: Breast cancer is a form of cancer that typically affects females. In general, cancer is caused by an imbalance between oncogene and supressor gene factors, including immunity factors against cancer cells. This study aims to compare the levels
Tutik Harjianti, Andi Fachruddin, Rahmawati Minhajat, Sahyuddin Saleh, Dimas Bayu   +4 more
doaj  

Anticancer evaluation of N-benzoyl-3-allylthiourea as potential antibreast cancer agent through enhances HER-2 expression

Journal of Advanced Pharmaceutical Technology & Research, 2020
Breast cancer with HER-2 overexpression is sensitive to drugs which target the receptor or its kinase activity. Although the anti-HER-2 therapies commonly used have improved patient outcome, resistance usually occurs.
Tri Widiandani, Siswandono, Edy Meiyanto
doaj   +1 more source

Therapeutic significance of hormone receptor positivity in patients with HER-2 positive breast cancer

Biomedical Papers, 2019
Breast cancer with high expression of human epidermal growth factor receptor (HER)-2 represents a biologically and clinically heterogeneous group of neoplastic disorders. Importantly, hormone receptor expression has an effect on biological properties and
Iveta Kolarova, Jaroslav Vanasek, Karel Odrazka, Bohuslav Melichar, Ales Ryska, Jiri Petera, Milan Vosmik, Martin Dolezel   +7 more
doaj   +1 more source

Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model

OncoImmunology, 2020
Therapeutic blockade of PD-1/PD-L1 signaling with monoclonal antibodies (mAbs) has shown clinical success and activity across a broad set of cancer subtypes.
Pravin T. P. Kaumaya, Linlin Guo, Jay Overholser, Manuel L. Penichet, Tanios Bekaii-Saab   +4 more
doaj   +1 more source

Expression of PCNA, CD-31 and HER-2 in Serbian patients with oral squamous cell carcinoma [PDF]

Archives of Biological Sciences, 2019
Several studies have investigated the expression of tumor markers, including p53, HER-2, PCNA, EGFR, VEGFR CD-31 and Bcl-2 in patients with oral squamous carcinoma (OSC). This study aimed to determine the expression of proliferating cell nuclear
Lončarević Slobodan A., Brajković Denis O., Gardašević Milka F., Lončarević Olivera Lj., Lađević Nebojša G., Nešić Dejan M., Stamenković Dušica M., Likić-Lađević Ivana S., Lađević Nikola N., Rančić Nemanja K.   +9 more
doaj   +1 more source

Preclinical HER-2 vaccines: from rodent to human HER-2

Frontiers in Oncology, 2013
Effective prevention of human cancer with vaccines against viruses, such as HBV and HPV, raises the question whether also non-virus related tumors could be prevented with immunological means. Studies in HER-2-transgenic mice showed that powerful anti-HER-
Pier-Luigi eLollini, Carla eDe Giovanni, Patrizia eNanni   +2 more
doaj   +1 more source